Please login to the form below

Not currently logged in
Email:
Password:

Clinigen appoints Shaun Chilton as COO of services division

Former KnowledgePoint360 Group president and MD will head both Keats Healthcare and Clinigen GAP

Clinigen, the UK-based specialty pharmaceutical and pharma services provider, has appointed Shaun Chilton to the newly-created role of chief operating officer of the group's services division.

Chilton joins from healthcare information supplier KnowledgePoint360 Group, where he was both president and managing director.

In his new role he will head both Clinigen's clinical trial supply business Keats Healthcare and Clinigen GAP, a specialist provider of early- and late-lifecycle prescription drugs, streamlining the two businesses.

Keats Healthcare, which was acquired by Clinigen in 2010, is currently being rebranded as Clinigen CTS.

Commenting on the appointment, Chilton said: “Keats Healthcare and Clinigen GAP are already successful businesses providing standalone services, but they are highly complementary and synergies between the two companies make their combination into a services division compelling.”

He joins the company from KnowledgePoint360 Group, a supplier of healthcare information, and prior to that held positions in sales and marketing at both Pfizer and Sanofi.

Peter George, CEO of Clinigen, said: “Shaun has a strong track record of building and leading high-performance sales and operational teams; driving commercial growth from international businesses; developing highly effective strategies, including major restructurings; and executing new strategies to deliver business goals, improve profitability and meet challenging targets.”

23rd January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics